LKFTLakefront Biotherapeutics NV
$31.64-7.2% 1Y
$31.64
$26.0752 weeks$34.64
Is the business good?
Mixed
1 neutral, 3 without dataMargins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 yearsStablederived
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
Customers and suppliers
Who buys from LKFT and who it buys from, as the companies report it.
97%of revenue comes from Gilead Sciences
Customerswho buys
- GILDGilead Sciences97%
Share of revenue · FY2025 20-F
Supplierswho it buys from
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; LKFT’s own figures are from its FY2025 20-F. Smaller customers and suppliers go unreported.